Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
RanBPM (show RANBP9 ELISA Kits) acts as a negative regulator of BLT2 and IL8 (show IL8 ELISA Kits), thus attenuating the invasiveness of aggressive breast cancer cells
BLT2 inhibition induces apoptosis, inhibits proliferation, colony formation and self-renewal capacity of CD34 (show CD34 ELISA Kits)(+) cells from tyrosine kinase (show TXK ELISA Kits) inhibitor - resistant blast phase-chronic myeloid leukemia (show BCL11A ELISA Kits) patients.
Data show that signal transducer and activator of transcription-3 (STAT-3 (show STAT3 ELISA Kits)) activation occurs downstream of leukotriene B4 receptor-2 (BLT2) and mediates cisplatin resistance in SK-OV-3 cells.
Authors demonstrated that MyD88 (show MYD88 ELISA Kits) lies upstream of BLT2 in LPS (show IRF6 ELISA Kits)-potentiated invasiveness and that this 'MyD88 (show MYD88 ELISA Kits)-BLT2' cascade mediates activation of NF-kappaB (show NFKB1 ELISA Kits) and the synthesis of IL-6 (show IL6 ELISA Kits) and IL-8 (show IL8 ELISA Kits) critical for the invasiveness and aggression of breast cancer cells.
BLT1 and BLT2 are therefore potential targets for the development of novel drugs.
searched BLT2 downstream components and identified reactive oxygen species and nuclear factor kappaB as critical components that contribute to epithelial-mesenchymal transition in mammary epithelial cells
BLT2-NOX-ROS (show ROS1 ELISA Kits)-NF-kappaB (show NFKB1 ELISA Kits) cascade induction during detachment confers a novel mechanism of anoikis resistance in prostate cancer cells and potentially contributes to prostate cancer progression.
RanBPM (show RANBP9 ELISA Kits) acts as a negative regulator of BLT2 signaling to attenuate BLT2-mediated cell motility
Findings indicate that BLT2 has a protective role in allergic airway inflammation and that diminished BLT2 expression in CD4 (show CD4 ELISA Kits)(+) T cells may contribute to the pathophysiology of asthma.
BLT2 is a novel therapeutic target that sensitises drug-resistant breast cancer cells to paclitaxel.
findings suggest that a leukotriene B4 receptor-2-linked cascade plays a pivotal role in LPS/TLR4 (show TLR4 ELISA Kits) signaling for IL-13 (show IL13 ELISA Kits) synthesis in mast cells, thereby potentially exacerbating allergic response.
This study demonstrates that LTB4 (show PTGR1 ELISA Kits) promotes macrophage phagocytosis of bacteria via BLT1, and that BLT2 can fulfill this role in the absence of BL
BLT2 expression in mast cells is essential for the production of VEGF in OVA-induced allergic asthma.
These results show that 12-HHT (show ACVRL1 ELISA Kits)/BLT2 enhances epithelial barrier function by increasing CLDN4 (show CLDN4 ELISA Kits) expression via the Galphai protein-p38 MAPK (show MAPK14 ELISA Kits) pathway.
Data indicate that leukotriene B4 receptor 2 protein BLT2-deficient mice exhibited impaired re-epithelialization and delayed wound closure after skin punching.
Leukotriene B4 receptor-2 promotes invasiveness and metastasis of ovarian cancer cells through signal transducer and activator of transcription 3 (STAT3 (show STAT3 ELISA Kits))-dependent up-regulation of matrix metalloproteinase 2 (show MMP2 ELISA Kits)
Selective inhibition of the BLT2 receptor in mice reduces the release of vascular reactive oxygen species and improves endothelial function in mice
Results suggest a direct anti-inflammatory role of BLT2 that is distinct from the proinflammatory roles of BLT1.
our results suggest that the BLT2-Nox1 (show NOX1 ELISA Kits)-reactive oxygen species cascade is a previously unsuspected mediatory signaling mechanism to Th2 cytokine production in Ag-stimulated BMMCs
mouse homolog is a chemoattractant for myeloid leukocytes
leukotriene B4 receptor 2
, LTB4 receptor JULF2
, leukotriene B4 receptor BLT2
, seven transmembrane receptor BLTR2
, LTB4-R 2